Omega-3多不饱和脂肪酸预防动静脉瘘和移植物失败:随机对照试验的系统综述与Meta分析
该系统综述与Meta分析纳入5项随机对照试验共833例血液透析患者,比较围手术期Omega-3多不饱和脂肪酸(Omega-3 PUFA)与安慰剂对动静脉通路结局的影响。中等确定性证据表明Omega-3 PUFA可能预防主要通畅性丧失(RR 0.81,95%CI 0.68-0.98),但对透析适用性失败、通路废弃、干预需求或全因死亡率可能无影响。出血和胃肠道副作用风险不确定。
要点
- Omega-3 PUFA可能减少动静脉通路主要通畅性丧失(中等确定性)。
- 对透析适用性失败、通路废弃、干预需求和全因死亡率可能无显著影响。
- 出血和胃肠道副作用风险不确定,需个体化评估。
核心结论
- Omega-3 PUFA补充可能预防动静脉通路主要通畅性丧失,但对透析适用性失败、通路干预或通路废弃可能无影响或影响很小。
- 潜在治疗危害不确定。
研究设计与样本
- 系统综述与Meta分析,纳入5项随机对照试验,共833例需要血液透析的成人患者,使用动静脉瘘或移植物。
- 中位随访12个月,比较围手术期Omega-3 PUFA补充与安慰剂。
- 检索CENTRAL、MEDLINE和Embase至2017年1月24日。
主要发现
- Omega-3 PUFA预防主要通畅性丧失(761例参与者,RR 0.81,95%CI 0.68-0.98,中等确定性)。
- 对透析适用性失败可能无影响或影响很小(536例参与者,RR 0.95,95%CI 0.73-1.23,低质量证据)。
- 对通路废弃可能无影响或影响很小(732例参与者,RR 0.78,95%CI 0.59-1.03,低质量证据)。
- 对维持通畅或辅助成熟的干预需求可能无影响或影响很小(732例参与者,RR 0.82,95%CI 0.64-1.04,低质量证据)。
- 对全因死亡率可能无影响或影响很小(799例参与者,RR 0.99,95%CI 0.51-1.92,低质量证据)。
关键数值与推荐
- 出血风险不确定(793例参与者,RR 1.40,95%CI 0.78-2.49)。
- 胃肠道副作用不确定(816例参与者,RR 1.22,95%CI 0.64-2.34)。
- 移植物和瘘之间未发现治疗效应不同的证据。
临床怎么用
- 对于血液透析患者,可考虑围手术期补充Omega-3 PUFA以降低动静脉通路主要通畅性丧失风险。
- 需权衡潜在不确定的出血和胃肠道副作用风险。
局限性
- 纳入试验数量少且存在方法学局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Arteriovenous access failure frequently occurs in people on hemodialysis and is associated with morbidity, mortality and large healthcare expenditures. Omega-3 polyunsaturated fatty acids (omega-3 PUFA) may improve access outcomes via pleiotropic effects on access maturation and function, but may cause bleeding complications. STUDY DESIGN: Systematic review with meta-analysis. SETTING & POPULATION: Adults requiring hemodialysis via arteriovenous fistula or graft. SELECTION CRITERIA: Trials evaluating omega-3 PUFA for arteriovenous access outcomes identified by searches in CENTRAL, MEDLINE, and Embase to 24 January 2017. INTERVENTION: Omega-3 PUFA. OUTCOMES: Primary patency loss, dialysis suitability failure, access abandonment, interventions to maintain patency or assist maturation, bleeding, gastrointestinal side-effects, all-cause and cardiovascular mortality, hospitalization, and treatment adherence. Treatment effects were summarized as relative risks (RR) and 95% confidence intervals (CI). Evidence was assessed using GRADE. RESULTS: Five eligible trials (833 participants) with a median follow-up of 12 months compared peri-operative omega-3 PUFA supplementation with placebo. One trial (n=567) evaluated treatment for fistulae and four (n=266) for grafts. Omega-3 PUFA supplementation prevented primary patency loss with moderate certainty (761 participants, RR 0.81, CI 0.68-0.98). Low quality evidence suggested, that omega-3 PUFA may have had little or no effect on dialysis suitability failure (536 participants, RR 0.95, CI 0.73-1.23), access abandonment (732 participants, RR 0.78, CI 0.59-1.03), need for interventions (732 participants, RR 0.82, CI 0.64-1.04), or all-cause mortality (799 participants, RR 0.99, CI 0.51-1.92). Bleeding risk (793 participants, RR 1.40, CI 0.78-2.49) or gastrointestinal side-effects (816 participants, RR 1.22, CI 0.64-2.34) from treatment were uncertain. There was no evidence of different treatment effects for grafts and fistulae. LIMITATIONS: Small number and methodological limitations of included trials. CONCLUSIONS: Omega-3 PUFA supplementation probably protects against primary loss of arteriovenous access patency, but may have little or no effect on dialysis suitability failure, access interventions or access abandonment. Potential treatment harms are uncertain.
引用
- Viecelli AK, Irish AB, Polkinghorne KR, et al. Omega-3 Polyunsaturated Fatty Acid Supplementation to Prevent Arteriovenous Fistula and Graft Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Kidney Dis. 2018. PMID: 29395485. doi:10.1053/j.ajkd.2017.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。